273 related articles for article (PubMed ID: 30125515)
41. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
42. Molecular Imaging of Newly Diagnosed Prostate Cancer.
Williams S
Cancer J; 2020; 26(1):43-47. PubMed ID: 31977384
[TBL] [Abstract][Full Text] [Related]
43. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
44. PET Tracers Beyond FDG in Prostate Cancer.
Schuster DM; Nanni C; Fanti S
Semin Nucl Med; 2016 Nov; 46(6):507-521. PubMed ID: 27825431
[TBL] [Abstract][Full Text] [Related]
45. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
46. PSMA and FDG PET/CT Findings in Patient With Dedifferentiated Liposarcoma and Prostate Cancer Metastases.
Liao X; Sun H; Chen X; Fan Y; Zhang J
Clin Nucl Med; 2024 Jul; 49(7):652-654. PubMed ID: 38689438
[TBL] [Abstract][Full Text] [Related]
47. Simultaneous whole-body
Freitag MT; Kesch C; Cardinale J; Flechsig P; Floca R; Eiber M; Bonekamp D; Radtke JP; Kratochwil C; Kopka K; Hohenfellner M; Stenzinger A; Schlemmer HP; Haberkorn U; Giesel F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):340-347. PubMed ID: 29038888
[TBL] [Abstract][Full Text] [Related]
48. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
[TBL] [Abstract][Full Text] [Related]
50. PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?
Rowe SP; Mana-Ay M; Javadi MS; Szabo Z; Leal JP; Pomper MG; Pienta KJ; Ross AE; Gorin MA
Clin Genitourin Cancer; 2016 Feb; 14(1):e115-8. PubMed ID: 26603549
[No Abstract] [Full Text] [Related]
51. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
52. PET Tracer
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
[No Abstract] [Full Text] [Related]
53. PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM; Rauscher I; Bluemel C; Fendler WP; Rowe SP; Pomper MG; Afshar-Oromieh A; Herrmann K; Eiber M
J Nucl Med; 2017 Oct; 58(10):1545-1552. PubMed ID: 28687599
[TBL] [Abstract][Full Text] [Related]
54. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
55. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
56. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
Langsteger W; Heinisch M; Fogelman I
Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
[TBL] [Abstract][Full Text] [Related]
57. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Sheikhbahaei S; Afshar-Oromieh A; Eiber M; Solnes LB; Javadi MS; Ross AE; Pienta KJ; Allaf ME; Haberkorn U; Pomper MG; Gorin MA; Rowe SP
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2117-2136. PubMed ID: 28765998
[TBL] [Abstract][Full Text] [Related]
58. 68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
Ahuja A; Taneja S; Thorat K; Jena A
Clin Nucl Med; 2017 Dec; 42(12):e509-e510. PubMed ID: 29036003
[TBL] [Abstract][Full Text] [Related]
59. Positron-emission tomography in imaging and staging prostate cancer.
Farsad M; Schiavina R; Franceschelli A; Sanguedolce F; Castellucci P; Bertaccini A; Brunocilla E; Manferrari F; Concetti S; Garofalo M; Rocca C; Borghesi M; Franchi R; Fanti S; Nanni C; Martorana G
Cancer Biomark; 2008; 4(4-5):277-84. PubMed ID: 18957716
[TBL] [Abstract][Full Text] [Related]
60. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]